scholarly journals Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study

2016 ◽  
Vol 33 (9) ◽  
pp. 1612-1627 ◽  
Author(s):  
Kazuhide Kawase ◽  
◽  
Jason L. Vittitow ◽  
Robert N. Weinreb ◽  
Makoto Araie
Keyword(s):  
Ocular Hypertension ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Safety And Efficacy ◽  
Japanese Subjects

Long-term Follow-up of Diode Laser Trabeculoplasty for Primary Open-angle Glaucoma and Ocular Hypertension

Ophthalmology ◽  
1993 ◽  
Vol 100 (11) ◽  
pp. 1614-1618 ◽  
Author(s):  
Anthony P. Moriarty ◽  
J. Dominic A. McHugh ◽  
Timothy J. ffytche ◽  
John Marshall ◽  
A.M. Peter Hamilton
Keyword(s):  
Ocular Hypertension ◽  
Diode Laser ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Laser Trabeculoplasty ◽  
Long Term Follow Up

scholarly journals Trabeculectomy with Ologen implant versus perfluoropropane gas bubble for open angle glaucoma in pseudophakic eyes

2021 ◽  
Vol 14 (4) ◽  
pp. 510-516
Author(s):  
Ahmed S Elwehidy ◽  
◽  
Hossam Youssef Abouelkheir ◽  
Waleed Abou Samra ◽  
Faried M Wagdy ◽  
...  
Keyword(s):  
Open Angle Glaucoma ◽  
Randomized Study ◽  
Study Groups ◽  
Gas Bubble ◽  
Open Angle ◽  
Safety And Efficacy ◽  
Group I ◽  
The Mean

AIM: To evaluate the safety and efficacy of augmented trabeculotomy with Ologen versus perfluoropropane in management of pseudophakic glaucoma. METHODS: This is a comparative randomized study included 57 pseudophakic eyes of 57 patients with medically uncontrolled open angle glaucoma (OAG). Twenty-nine patients were allocated in group I (trabeculectomy with Ologen; trab-ologen group), while 28 patients were assigned in group II (trabeculectomy with perfluoropropane gas bubble; trab-C3F8 gas bubble group). RESULTS: The intraocular pressure (IOP) was significantly reduced in both study groups at all postoperative follow up intervals (1wk, 3, 6, 12, 18, 24, 30 and 36mo, P<0.001). The differences between the mean IOP values of both groups remained statistically insignificance during the early 12 months of follow up. However, the trab-ologen group achieved a statistically significant reduction over the trab-C3F8 gas bubble group during the last 24 months of follow up. CONCLUSION: Augmentation of trabeculectomy with either Ologen implant or perfluoropropane gas bubble are associated with strict long term IOP control and evident safety in medically-uncontrolled pseudophakic eyes with OAG.

scholarly journals Adjunctive therapy with brinzolamide in patients on travoprost treatment

2011 ◽  
Vol 64 (5-6) ◽  
pp. 310-314
Author(s):  
Nikola Babic ◽  
Veljko Andreic ◽  
Aleksandar Miljkovic ◽  
Vladimir Canadanovic ◽  
Sava Barisic
Keyword(s):  
Intraocular Pressure ◽  
Ocular Hypertension ◽  
Adjunctive Therapy ◽  
Open Angle Glaucoma ◽  
Combined Therapy ◽  
Previous Treatment ◽  
Open Angle ◽  
Open Label ◽  
Blurred Vision ◽  
Safety And Efficacy

Introduction. This study was aimed at evaluating the safety and efficacy of brinzolamide 1% suspension (Azopt? 1%) and travoprost 0.004% (Travatan?) combined therapy in patients with open-angle glaucoma or ocular hypertension who are in need of additional intraocular pressure lowering. Material and methods. This is a prospective, three-month, open-label, clinical study. Forty patients (80 eyes) with primary open-angle glaucoma or ocular hypertension on Travatan? treatment and with unsatis-factory results in lowering intraocular pressure were included in the study. The qualifying intraocular pressure on previous treatment with Travatan? (at least 6 weeks) was 22-36 mmHg in at least one eye at 8 a.m. intraocular pressure measurements at three eligibility visits. The patients received brinzolamide 1% twice a day in addition to travoprost 0.004% given once a day in the evening for 3 months. The follow-up examinations assessing the safety and efficacy of combined therapy of brinzolamide 1% and travoprost 0.004% were performed after 1 and 3 months. Results. Adjunctive therapy with brinzolamide resulted in statistically significant reductions in intraocular pressure from the travoprost baseline at all visits. Treatment with brinzolamide/travoprost caused statistically significant sustained reduction in intraocular pressure with the reduction of 17.39% (p<0.001) after 4 weeks and 20.08% (p<0.001) after 12 weeks. The intraocular pressure change from the baseline ranged from -3.9 mmHg after 4 weeks to -4.48 mmHg after 12 weeks. The most frequently related adverse effect was abnormal taste and blurred vision. Conclusion. Brinzolamide 1% (b.i.d.) used adjunctively with travoprost 0.004% (q.d.) lowers intraocular pressure significantly compared to travoprost alone. Both drugs were well tolerated and safe in the studied patients.

Sign in / Sign up

Export Citation Format

Share Document